(1S,2R)-2-(1-methylhydrazino)-1,2-diphenylethanol | 70708-44-0

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 二苯乙烯类
• 英文名称: (1S,2R)-2-(1-methylhydrazino)-1,2-diphenylethanol
• 英文别名: (1S,2R)-2-[amino(methyl)amino]-1,2-diphenylethanol
• CAS: 70708-44-0
• 化学式: C₁₅H₁₈N₂O
• 分子量: 242.321
• InChiKey: UZSBWSNIXUXPDF-CABCVRRESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  18
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  49.5
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  D-酒石酸 、 (1S,2R)-2-(1-methylhydrazino)-1,2-diphenylethanol 以 乙醚 、 乙醇 为溶剂， 以1.24 g的产率得到(1S,2R)-2-(1-methylhydrazino)-1,2-diphenylethanol hemi-(S,S)-tartrate
  参考文献：
  名称：

  Novel Hydrazine Molecules as Tools To Understand the Flexibility of Vascular Adhesion Protein-1 Ligand-Binding Site: Toward More Selective Inhibitors

  摘要：

  Vascular adhesion protein-1 (VAP-1) belongs to a family of amine oxidases. It plays a role in leukocyte trafficking and in amine compound metabolism. VAP-1 is linked to various diseases, such as Alzheimer's disease, psoriasis, depression, diabetes, and obesity. Accordingly, selective inhibitors of VAP-1 could potentially be used to treat those diseases. In this study, eight novel VAP-1 hydrazine derivatives were synthesized and their VAP-1 and monoamine oxidase (MAO) inhibition ability was determined in vitro. MD simulations of VAP-1 with these new molecules reveal that the VAP-1 ligand-binding pocket is flexible and capable of fitting substantially larger ligands than was previously believed. The increase in the size of the VAP-1 ligands, together with the methylation of the secondary nitrogen atom of the hydrazine moiety, improves the VAP-1 selectivity over MAO.

  DOI：

  10.1021/jm200059p
• 作为产物：
  描述：

  N-[(1R,2S)-2-hydroxy-1,2-diphenylethyl]-N-methylnitrous amide 在 lithium aluminium tetrahydride 作用下， 以 四氢呋喃 为溶剂， 生成 (1S,2R)-2-(1-methylhydrazino)-1,2-diphenylethanol
  参考文献：
  名称：

  Novel Hydrazine Molecules as Tools To Understand the Flexibility of Vascular Adhesion Protein-1 Ligand-Binding Site: Toward More Selective Inhibitors

  摘要：

  Vascular adhesion protein-1 (VAP-1) belongs to a family of amine oxidases. It plays a role in leukocyte trafficking and in amine compound metabolism. VAP-1 is linked to various diseases, such as Alzheimer's disease, psoriasis, depression, diabetes, and obesity. Accordingly, selective inhibitors of VAP-1 could potentially be used to treat those diseases. In this study, eight novel VAP-1 hydrazine derivatives were synthesized and their VAP-1 and monoamine oxidase (MAO) inhibition ability was determined in vitro. MD simulations of VAP-1 with these new molecules reveal that the VAP-1 ligand-binding pocket is flexible and capable of fitting substantially larger ligands than was previously believed. The increase in the size of the VAP-1 ligands, together with the methylation of the secondary nitrogen atom of the hydrazine moiety, improves the VAP-1 selectivity over MAO.

  DOI：

  10.1021/jm200059p

文献信息

• NEW PYRIDAZINONE AND PYRIDONE COMPOUNDS
  申请人：Pihlavisto Marjo

  公开号：US20140024648A1

  公开（公告）日：2014-01-23

  The invention relates to pyridazinone and pyridone compounds having formula (I) or (I′), and pharmaceutically acceptable salts, hydrates, and solvates thereof (I) wherein R 1 /R 4 and X and X 3 are as defined in the claims. The invention further relates to their use as inhibitors of copper-containing amine oxidases. The present invention also relates to the preparation of the aforementioned compounds and to pharmaceutical compositions comprising as an active ingredient(s) one or more of the aforementioned compounds, pharmaceutically acceptable salts, hydrates, or solvates thereof.

  本发明涉及具有式（I）或（I'）的吡啶并咪唑酮和吡啶酮化合物，以及其药学上可接受的盐、水合物和溶剂化物（I）其中R1/R4和X和X3如权利要求中所定义。本发明进一步涉及它们作为含铜胺氧化酶的抑制剂的用途。本发明还涉及制备上述化合物以及包含作为活性成分的制药组合物，其中活性成分是上述化合物之一或多个，其药学上可接受的盐、水合物或溶剂化物。
• PYRIDAZINONE AND PYRIDONE COMPOUNDS
  申请人：BIOTIE THERAPIES CORPORATION

  公开号：US20160244414A1

  公开（公告）日：2016-08-25

  The invention relates to pyridazinone and pyridone compounds having formula (I) or (I′), and pharmaceutically acceptable salts, hydrates, and solvates thereof wherein R 1 /R 4 and X and X 3 are as defined in the claims. The invention further relates to their use as inhibitors of copper-containing amine oxidases. The present invention also relates to the preparation of the aforementioned compounds and to pharmaceutical compositions comprising as an active ingredient(s) one or more of the aforementioned compounds, pharmaceutically acceptable salts, hydrates, or solvates thereof.

  本发明涉及具有式（I）或（I'）的吡啶嗪和吡啶酮化合物，以及其药学上可接受的盐，水合物和溶剂化物，其中R1 / R4和X和X3如权利要求所定义。本发明进一步涉及它们作为含铜胺氧化酶的抑制剂的用途。本发明还涉及前述化合物的制备以及包含作为活性成分的制药组合物之一或多个前述化合物，药学上可接受的盐，水合物或溶剂化物。
• Pyridazinone and pyridone compounds
  申请人：BIOTIE THERAPIES CORPORATION

  公开号：US10479771B2

  公开（公告）日：2019-11-19

  The invention relates to pyridazinone and pyridone compounds having formula (I) or (I′), and pharmaceutically acceptable salts, hydrates, and solvates thereof wherein R1/R4 and X and X3 are as defined in the claims. The invention further relates to their use as inhibitors of copper-containing amine oxidases. The present invention also relates to the preparation of the aforementioned compounds and to pharmaceutical compositions comprising as an active ingredient(s) one or more of the aforementioned compounds, pharmaceutically acceptable salts, hydrates, or solvates thereof.

  本发明涉及具有式（I）或（I′）的哒嗪酮和吡啶酮化合物及其药学上可接受的盐、水合物和溶剂 其中R1/R4和X及X3如权利要求中所定义。本发明还涉及它们作为含铜胺氧化酶抑制剂的用途。本发明还涉及上述化合物的制备，以及含有一种或多种上述化合物、其药学上可接受的盐、水合物或溶液作为活性成分的药物组合物。
• Use of VAP-1 inhibitors for treating fibrotic conditions
  申请人：BIOTIE THERAPIES CORP.

  公开号：US10576148B2

  公开（公告）日：2020-03-03

  The present invention relates to inhibitors of VAP-1 and their use as medicaments in treating fibrotic conditions. Furthermore, the present invention relates to a method of diagnosing a fibrotic condition on the basis of elevated level of soluble VAP-1 or SSAO activity in a bodily fluid, and to a kit for use in said diagnostic method.

  本发明涉及 VAP-1 的抑制剂及其在治疗纤维化病症中作为药物的用途。此外，本发明还涉及一种根据体液中可溶性 VAP-1 或 SSAO 活性水平升高来诊断纤维化病症的方法，以及用于上述诊断方法的试剂盒。
• USE OF VAP-1 INHIBITORS FOR TREATING FIBROTIC CONDITIONS
  申请人：Weston Christopher

  公开号：US20130195883A1

  公开（公告）日：2013-08-01

  The present invention relates to inhibitors of VAP-1 and their use as medicaments in treating fibrotic conditions. Furthermore, the present invention relates to a method of diagnosing a fibrotic condition on the basis of elevated level of soluble VAP-1 or SSAO activity in a bodily fluid, and to a kit for use in said diagnostic method.